Mebicar® Instruction

International Non-Proprietary Name (INN): mebicar
Dosage form: pills (300 mg or 500 mg)
Structure
1 pill contains:
Active ingredient: mebicar 300 mg or 500 mg.
Excipients: povidone (high-molecular polyvinylpyrrolidone), calcium stearate.
Description
Flat cylindrical pills of white color with a facet and a break line.
Pharmacological classification: tranquilizer (anxiolytic)
ATC code: N05BX
Pharmacological action: anxiolytic, stress-protective, nootropic, cardioprotective

adaptol mebicar sq
Mebicar® 2


Pharmacodynamics

Mebicar is an anxiolytic, stress-protective, nootropic medication. It enhances oxygen supply in myocardial tissues; improves electrolyte balance disorders of the blood, improves the content of potassium ions in the plasma, in erythrocytes, and in myocardium cells; potentiates protein synthesis and increase of the cell energy potential.

Mebicar normalizes sleeping if disturbed without having direct hypnotic action. It does not have a cholinolytic and myorelaxing effect. It does not disturb motor performance. It mitigates or relieves nicotine withdrawal symptoms.

Pharmacokinetics

Absorption: 78–80% of the dosage is absorbed into the blood. The maximum concentration of the active ingredient in blood is reached in 0.5 hours after taking the drug.

Distribution: Mebicar is freely distributed throughout the organism and it freely comes through the cell membranes.

Excretion: Fully excretes from the body in urine within 24 hours.

Intended uses

  • neurotic disorders (irritability, emotional instability, anxiety, anxio-depressive, phobic, panic disorders) which come as a result of exhausting psychoemotional, neuropsychic and physical activities;
  • (as part of complex therapy) treating patients with cardialgia, coronary heart disease and for rehabilitation after myocardial infarction;
  • reduction of tobacco addiction;
  • treatment of neurosis-like states of patients who suffer from alcohol dependence, reduction of the morbid addiction to the alcohol and to psychoactive substances;
  • improvement of tolerability to neuroleptics and tranquilizers.


Contraindications

  • hypersensitivity to the components of the drug;
  • age below 18 years;
  • pregnancy and lactation.


Dosage and administration

Ingest by mouth without regard to timing of food: 300–900 mg 2-3 times a day.

The maximum single dosage is 3 g; the maximum daily dosage is 10 g. The length of the treatment varies from several days to 2-3 months. Depending on the patient’s condition, in case of mental disorders – up to 6 months.

With irritability, fear, emotional lability, anxiety
It is recommended to administer 300–600 mg 3 times a day.

With vegetative and mental disorders (including anxiety, fear, loss of attention and memory, asthenia, not associated with coronary artery disease)
It is recommended to take 600–900 mg of the drug 3 times a day.

To reduce the craving for alcohol and nicotine, as well as for nicotine and alcohol abstinence
It is recommended to take 600–900 mg of the drug 3 times a day. The duration of the treatment course lasts up to 1.5 months.

Patients with severe psychopathic disorders caused by organic brain changes and with the development of intolerance to neuroleptic drugs
900–1800 mg of the drug 3 times a day.

Side effects

Allergic reactions (skin rashes, itching), a decrease of arterial pressure, hyperthermia, dyspepsia.

Decrease of arterial pressure or body temperature do not require cessation of treatment. Blood pressure and body temperature return to normal on their own.

Overdose

The toxicity of Mebicar is very low. Severe overdose is likely to increase the severity of side effects. In such cases, it is necessary to conduct conventional treatment for detoxification.

Interaction with other drugs

Mebicar potentiates the effect of hypnotic and narcotic drugs.

Pregnancy and lactation

Due to the lack of clinical research data, Mebicar is not recommended during pregnancy and lactation. If you need to take the drug during lactation, breastfeeding should be discontinued.

Influence on the ability to drive vehicles and operate mechanisms

Special caution should be taken during the treatment period when driving vehicles and operating mechanisms.

Terms of release from pharmacy

On prescription.

Storage conditions

Store in dry places at room temperature. Keep out of reach of children.

Shelf life

4 years. Do not use beyond the expiration date.

Manufacturer

TatChemPharmPreparaty, Russia. https://www.tatpharm.ru/eng/

Thank you!

You will now receive regular updates from us!